[go: up one dir, main page]

AR051945A1 - Formas polimorficas de 6-[2-(metilcarbamoil)fenilsulfanil] -3-e-[2-(piridin-2-il) etenil] indazol - Google Patents

Formas polimorficas de 6-[2-(metilcarbamoil)fenilsulfanil] -3-e-[2-(piridin-2-il) etenil] indazol

Info

Publication number
AR051945A1
AR051945A1 ARP050104569A ARP050104569A AR051945A1 AR 051945 A1 AR051945 A1 AR 051945A1 AR P050104569 A ARP050104569 A AR P050104569A AR P050104569 A ARP050104569 A AR P050104569A AR 051945 A1 AR051945 A1 AR 051945A1
Authority
AR
Argentina
Prior art keywords
polymorphic forms
metilcarbamoil
sulfanil
piridin
ethylen
Prior art date
Application number
ARP050104569A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR051945A1 publication Critical patent/AR051945A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Tales formas polimorficas pueden ser un componente de una composicion farmacéutica y se pueden usar para tratar un trastorno hiperproliferativo o una afeccion patologica de mamífero mediada por la actividad de la proteína quinasa. Reivindicacion 1:Una forma cristalina de 6-[2-(metilcarbamoil)fenilsulfanil]-3-E-[2-(piridin-2-il)etenil]indazol, representado por la formula (1) o una sal farmacéuticamente aceptable del mismo.
ARP050104569A 2004-11-02 2005-11-01 Formas polimorficas de 6-[2-(metilcarbamoil)fenilsulfanil] -3-e-[2-(piridin-2-il) etenil] indazol AR051945A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62466504P 2004-11-02 2004-11-02

Publications (1)

Publication Number Publication Date
AR051945A1 true AR051945A1 (es) 2007-02-21

Family

ID=35538878

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104569A AR051945A1 (es) 2004-11-02 2005-11-01 Formas polimorficas de 6-[2-(metilcarbamoil)fenilsulfanil] -3-e-[2-(piridin-2-il) etenil] indazol

Country Status (14)

Country Link
US (1) US20060094763A1 (es)
EP (1) EP1819696A1 (es)
JP (1) JP2008518904A (es)
KR (1) KR20070060145A (es)
AR (1) AR051945A1 (es)
AU (1) AU2005300317A1 (es)
BR (1) BRPI0517924A (es)
CA (1) CA2586177A1 (es)
IL (1) IL182580A0 (es)
MX (1) MX2007005273A (es)
RU (1) RU2007116150A (es)
TW (1) TW200630356A (es)
WO (1) WO2006048751A1 (es)
ZA (1) ZA200702976B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608952A1 (en) * 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
PT2134702T (pt) * 2007-04-05 2017-07-31 Pfizer Prod Inc Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-(piridin-2-il)etenil]indazol adequadas para o tratamento de crescimento celular anormal em mamíferos
AU2012313885A1 (en) 2011-09-30 2014-03-13 Pfizer Inc. Pharmaceutical compositions of N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide
EP2776031A1 (en) 2011-11-11 2014-09-17 Pfizer Inc N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN104140414B (zh) * 2013-05-07 2018-12-11 江苏豪森药业集团有限公司 阿昔替尼晶型的制备方法
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
SI3498734T1 (sl) 2014-02-04 2022-02-28 Pfizer Inc. Kombinacija antagonista PD-1 in zaviralca VEGFR za zdravljenje raka
JP2017530950A (ja) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
SG10201810615VA (en) 2015-02-26 2019-01-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
WO2016178150A1 (en) * 2015-05-05 2016-11-10 Shilpa Medicare Limited Novel polymorphs of axitinib
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
CN109843324A (zh) 2016-10-06 2019-06-04 辉瑞公司 用于治疗癌症的avelumab用药方案
WO2020003196A1 (en) * 2018-06-28 2020-01-02 Alembic Pharmaceuticals Limited Pharmaceutical composition of axitinib
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
US20220194921A1 (en) 2019-04-18 2022-06-23 Synthon B.V. Process for preparation of axitinib
JP2022532540A (ja) 2019-05-09 2022-07-15 シントン・ビー．ブイ． アキシチニブを含有する医薬組成物
AU2021244485B2 (en) 2020-03-25 2024-05-16 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN112174933A (zh) * 2020-08-07 2021-01-05 天津理工大学 一种阿西替尼富马酸盐的新晶型及其制备方法
CN114685436B (zh) * 2020-12-25 2022-12-02 鲁南制药集团股份有限公司 阿昔替尼糖精共晶水合物
CN114685437B (zh) * 2020-12-25 2022-12-09 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685431B (zh) * 2020-12-26 2022-11-29 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685432B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685435B (zh) * 2020-12-28 2023-01-31 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
CN114685433B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
CN114685438B (zh) * 2020-12-28 2023-06-13 鲁南制药集团股份有限公司 一种阿昔替尼苹果酸新盐
JP2024532454A (ja) 2022-03-03 2024-09-05 ファイザー・インク 多重特異性抗体およびその使用
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib
TW202448436A (zh) * 2023-04-11 2024-12-16 美商視爾普斯眼科公司 含有酪胺酸激酶抑制劑之眼部植入物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
AU2005300317A1 (en) 2006-05-11
IL182580A0 (en) 2007-07-24
JP2008518904A (ja) 2008-06-05
TW200630356A (en) 2006-09-01
WO2006048751A1 (en) 2006-05-11
CA2586177A1 (en) 2006-05-11
RU2007116150A (ru) 2008-11-10
ZA200702976B (en) 2008-08-27
EP1819696A1 (en) 2007-08-22
MX2007005273A (es) 2007-07-19
US20060094763A1 (en) 2006-05-04
BRPI0517924A (pt) 2008-10-21
KR20070060145A (ko) 2007-06-12

Similar Documents

Publication Publication Date Title
AR051945A1 (es) Formas polimorficas de 6-[2-(metilcarbamoil)fenilsulfanil] -3-e-[2-(piridin-2-il) etenil] indazol
EA200801716A1 (ru) Тиазольные соединения и их применение
JP2016517878A5 (es)
PE20120119A1 (es) AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
KR20090018593A (ko) 세포괴사 저해제로서의 인돌 및 인다졸 화합물
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
PE20060501A1 (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
UA97817C2 (ru) Гетероциклические производные 4-(метилсульфонил)фенила и их применение
KR20140081883A (ko) Lsd1 억제제로서의 (헤테로)아릴 사이클로프로필아민 화합물
RU2013153529A (ru) Новые соединения и композиции для ингибирования nampt
SI3009428T1 (en) DIAMINO HETEROCYCLIC CARBOSAMIDE COMPOUNDS
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
NZ746950A (en) Heterocyclic gpr119 agonist compounds
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
NZ630488A (en) Piperidine derivatives for gpr119 agonist
MX368157B (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
NZ610700A (en) Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate

Legal Events

Date Code Title Description
FB Suspension of granting procedure